BUDDE K ET AL: "First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients" JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 13, no. 4, 1 January 2002 (2002-01-01), pages 1073-1083, XP003016978 ISSN: 1046-6673 (B1)

DAVID KINSHUCK AT HEARTOFENGLAND NHS UK: 'Blood pressure and diabetes', [Online] 04 December 2006, XP055086741 Retrieved from the Internet: <URL:http://medweb.bham.ac.uk/easdec/preven tion/Diabetes%20and%20Blood%20Pressure.htm> [retrieved on 2013-11-05] (B1)

WO-A2-2009/048993 (B1)

Oral fingolimod (FTY720), 0.5 or 1.25 mg, for 14 days has no effect on cardiac function: "World Congresson Treatment and Research on Multiple Sclerosis"; "Abst P507" In: SCHMOULDER R., ET AL.: "Multiple Sclerosis" 17 September 2008 (2008-09-17), Sage , London , XP009127649 vol. 14, , page S177 the whole document (B1)

WO-A1-2006/058316 (B1)

KOYRAKH LEV ET AL: "The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I." March 2005 (2005-03), AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS MAR 2005, VOL. 5, NR. 3, PAGE(S) 529 - 536 , XP002562406 ISSN: 1600-6135 abstract page 534, right-hand column, paragraph 1-2; figure 5 (B1)